Latest News about REGN
Recent news which mentions REGN
   Earnings Scheduled For February 4, 2022
   
  
  
  February 04, 2022
  From Benzinga
 
   What This FDA News Could Mean for Pfizer
   
  
  
  February 01, 2022
  From Motley Fool
 
   Should Investors Sell Eli Lilly After This Recent Regulatory News?
   
  
  
  February 01, 2022
  From Motley Fool
 
   Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
   
  
  
  February 01, 2022
  From Benzinga
 
   3 Biotech Stocks That Could Boom or Bust in Q1
   
  
  
  February 01, 2022
  From InvestorPlace
 
   5 Things To Expect This Week
   
  
  
  January 31, 2022
  From InvestorPlace
 
   The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
   
  
  
  January 31, 2022
  From Benzinga
 
   CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
   
  
  
  January 31, 2022
  From Benzinga
 
   Market corrections are good buying opportunities, says Goldman Sachs — but only when this happens
   
  
  
  January 31, 2022
  From MarketWatch
 
   A Deep Dive Into the Video Game Industry
   
  
  
  January 29, 2022
  From Motley Fool
 
   Can AbbVie Beat Pfizer in the Atopic Dermatitis Market?
   
  
  
  January 29, 2022
  From Motley Fool
 From Benzinga
 From Benzinga
 From MarketWatch
 
   Pfizer and BioNTech launch study of omicron vaccine, and FDA halts use of two COVID antibody treatments
   
  
  
  January 25, 2022
  From MarketWatch
 
   A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting
   
  
  
  January 25, 2022
  From Benzinga
 
   FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
   
  
  
  January 24, 2022
  From Benzinga
 
   Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
   
  
  
  January 24, 2022
  From Benzinga
 
   Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
   
  
  
  January 19, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
   
  
  
  January 19, 2022
  From Benzinga
 
   Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
   
  January 19, 2022
  Tickers 
   REGN
  
  
  From Benzinga
 
   2 Top Biotech Stocks to Buy and Hold for 10 Years
   
  
  
  January 17, 2022
  From Motley Fool
 
   3 Top Biotech Stocks to Buy Right Now
   
  
  
  January 15, 2022
  From Motley Fool
 From Benzinga
 From Benzinga
 From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
